Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelizumab + apatinib + SOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400082624Phase 2Recruiting
- Sponsor
- Changshu No.2 People's Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, Rivoceranib, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Changshu No.2 People's Hospital. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranibtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400082624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082624.